computer program graphpad statmate (GraphPad Software Inc)
GraphPad Software Inc is a verified supplier 
90
Structured Review
GraphPad Software Inc
computer program graphpad statmate
Computer Program Graphpad Statmate, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/statmate+computer+program/computer+program+graphpad+statmate/pm10777122-32-36-38
Average 90 stars, based on 1 article reviews
Computer Program Graphpad Statmate, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/statmate+computer+program/computer+program+graphpad+statmate/pm10777122-32-36-38
Average 90 stars, based on 1 article reviews
computer program graphpad statmate - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Sequencing:Article Title: Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis. Article Snippet: Objective: To determine the effectiveness and tolerance of treatment with cyclosporine A (CyA) or methotrexate (MTX) added to corticosteroids in patients with severe, active polymyositis (PM) and dermatomyositis (DM).. Patients and methods: Thirty-six patients (20 with DM, 16 with PM) were enrolled into the study and randomized in MTX (n~17) and CyA (n~19) groups.. Muscle endurance and functional test (MEFT), clinical assessment (CA), global patient's assessment (GPA), muscle MRI, serum CK, myoglobin, IL-1Ra, and autoantibody status were used to assess the response to therapy after 1, 3, and 6 months. Generated:Article Title: Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis. Article Snippet: Objective: To determine the effectiveness and tolerance of treatment with cyclosporine A (CyA) or methotrexate (MTX) added to corticosteroids in patients with severe, active polymyositis (PM) and dermatomyositis (DM).. Patients and methods: Thirty-six patients (20 with DM, 16 with PM) were enrolled into the study and randomized in MTX (n~17) and CyA (n~19) groups.. Muscle endurance and functional test (MEFT), clinical assessment (CA), global patient's assessment (GPA), muscle MRI, serum CK, myoglobin, IL-1Ra, and autoantibody status were used to assess the response to therapy after 1, 3, and 6 months. |